70
Views
0
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

The role of maintenance therapy in the treatment of advanced urothelial cancer: a comprehensive systematic review and network meta-analysis

, , &
Pages 505-513 | Received 18 May 2022, Accepted 21 Nov 2022, Published online: 12 Dec 2022
 

Abstract

Concerns increase with maintenance therapy for advanced urothelial cancer (aUC). We perform a comprehensive network meta-analysis (NMA) to investigate the efficacy and toxicities of maintenance therapy in aUC patients. Trials assessing maintenance treatment with either a continuous or a switch strategy for aUC were identified. The primary outcome was overall survival (OS), and secondary outcome was progression-free survival (PFS) and toxicities. Nine articles reporting eight trials were included. The pooled hazard ratio demonstrated that maintenance therapy significantly improved OS giving HR 0.83 (95%CI: 0.74–0.93, P = 0.0013) and PFS with HR of 0.78 (95%CI: 0.62–0.99, P = 0.05), but increased the risk of developing severe adverse events and treated-related discontinues (P < 0.05). Sub-group analysis indicated that ‘switch’ ICI (immune checkpoint inhibitor) maintenance therapy significantly improved OS and PFS when compared to best support care (BSC) (P < 0.05). NMA showed that chemotherapy followed by ‘switch’ maintenance with ICI significantly improved OS (HR 0.70, 95%CI: 0.57–0.87) when compared to BSC. ‘Continuous’ maintenance with ICI alone had a tendency to improve OS (HR 0.85, 95%CI: 0.71–1.01), and TA (HR0.93, 95%CI: 0.58–1.50) and vinflunine (HR 0.74, 95%CI: 0.44–1.24) was no significantly associated with a lower likelihood of disease death. Based on the analysis of the treatment ranking, ‘switch’ maintenance with ICI appeared as the best treatment approach. Our pooled results confirm that maintenance therapy yields a significant survival advantage for aUC patients. NMA indicates that switch maintenance with ICI is the optimum maintenance treatment for aUC and reduces mortality by about a third.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author contributions

Conceptualization: X.T. and D.F. Project administration: W.F. and X.Z. Methodology: X.T., D.F., W.F. Data curation: X.T. and X.Z. Formal analysis: X.T. Manuscript preparation: X.T., D.F., X.Z. Final approval of manuscript: all authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.